Cancer remains the second leading cause of death worldwide, a vast group of diseases unified by one defining feature: uncontrolled cell proliferation. Despite decades of progress in surgery, chemotherapy, immunotherapy, and targeted agents, there is enormous interest in approaches that can either prevent malignant transformation or sensitize existing tumors to conventional treatments. Probiotics—most commonly strains of lactic acid bacteria and bifidobacteria—have emerged as intriguing candidates on both fronts, with studies suggesting they may act as prophylactics, as adjuvants that boost the efficacy of standard therapies, and even as direct anti-tumor agents.

What makes the new review particularly timely is its focus on postbiotics, a term that has gained substantial traction in recent years. Postbiotics are the non-living counterparts of probiotics: inactive microbial cells, cell wall components, and secreted metabolites that retain biological activity without the risks associated with administering live microorganisms. This distinction matters enormously in clinical contexts. Immunocompromised cancer patients, for instance, face real dangers from live bacterial supplementation, including sepsis. If the anti-cancer effects of probiotics can be reproduced with postbiotic preparations—heat-killed cells, purified cell fragments, or defined metabolic products—the field gains a potentially safer and more controllable therapeutic platform.

The review organizes the preclinical evidence around the major hallmarks of tumor cells, and the mechanisms it catalogues are strikingly diverse. Perhaps the most extensively documented is the induction of apoptosis, the programmed cell death that cancer cells characteristically evade. Studies cited in the review show that probiotic bacteria and their metabolites can trigger both intrinsic and extrinsic apoptotic pathways in tumor cells. The intrinsic route involves mitochondrial perturbation: pro-apoptotic proteins such as BAK, BIK, and BIM are upregulated, cytochrome c is released into the cytosol, and the caspase cascade is activated, ultimately cleaving PARP-1 and dismantling the cell. The extrinsic pathway proceeds through death receptors, engaging FAS-associated death domain protein (FADD) and downstream caspases. In several models, compounds such as the cellular inhibitor of apoptosis protein 2 (cIAP2) and SMAC—the second mitochondria-derived activator of caspase—appear as key regulatory nodes in this lethal signaling.

Equally compelling is the evidence that probiotics can arrest the cell cycle, the engine of tumor growth. Multiple studies described in the review report that bacterial treatments reduce the expression of proliferating cell nuclear antigen (PCNA), a protein essential for DNA replication, and interfere with cyclin-dependent kinases (CDKs) and their inhibitors (CKIs), the molecular switches that govern transitions between cell cycle phases. By blocking these transitions, probiotic metabolites effectively put tumor cells into a state of suspended division, preventing them from doubling their numbers. Some strains achieve this through epigenetic means as well: histone deacetylase (HDAC) inhibition has been observed, a mechanism shared with several approved anti-cancer drugs, since HDAC inhibitors can reactivate tumor suppressor genes silenced during malignant transformation.

Metabolic interference represents a third major axis of attack. Tumor cells famously rewire their metabolism, favoring fermentation of glucose even in the presence of oxygen—the so-called Warburg effect—to fuel rapid growth. The review details how probiotic-derived short chain fatty acids (SCFAs), particularly butyrate, propionate, and acetate, can disrupt this metabolic programming. Enzymes such as pyruvate kinase M2 (PKM2) and pyruvate dehydrogenase kinase 2 (PDK2), which help tumors maintain their preferred metabolic state, are influenced by bacterial metabolites, while AMP-activated protein kinase (AMPK), a cellular energy sensor, is activated in ways that are hostile to tumor survival. Conjugated linoleic acids (CLA) and conjugated α-linolenic acid (CLNA) produced by certain Lactobacillus and Bifidobacterium strains have also been shown to exert cytotoxic effects on cancer cells, adding lipid chemistry to the anti-tumor arsenal.

The immune dimension may be the most clinically resonant of all. The tumor microenvironment (TME) is a fortress that tumors construct around themselves, suppressing immune surveillance through regulatory T cells, suppressive cytokines, and checkpoint signaling. Probiotics appear to dismantle parts of this defense. By engaging pattern recognition receptors (PRRs) and C-type lectin receptors (CLRs) on antigen-presenting cells (APCs), bacterial components stimulate innate immunity and prime adaptive responses. The review describes how probiotic treatment increases the activity of cytotoxic T lymphocytes (CTLs) and natural killer cells, and upregulates MHC class I chain-related proteins A and B (MICA/B) on tumor cells—molecules that mark cancer cells for immune destruction. In animal models, combining probiotics with chemotherapy agents such as cyclophosphamide or 5-fluorouracil has produced synergistic effects, with the microbes restoring immune competence that the drugs alone suppress.

Metastasis, the process that makes cancer lethal in most cases, is another target. Probiotic strains and their exopolysaccharides (EPS) have been shown to inhibit matrix metalloproteases (MMPs), the enzymes tumors use to digest surrounding tissue, and to suppress epithelial-to-mesenchymal transition (EMT), the cellular program through which cancer cells gain migratory and invasive properties. Focal adhesion kinase (FAK), a central coordinator of cell motility, and vascular endothelial growth factor (VEGF), the master driver of tumor angiogenesis, are both dampened in response to certain bacterial treatments, suggesting that probiotics could choke off a tumor’s blood supply and limit its ability to spread.

Colorectal cancer features prominently throughout the review, and for good reason. The gut is where probiotics naturally reside, placing them in direct contact with the mucosal environment where colorectal tumors arise. Studies using chemically induced models—such as azoxymethane/dextran sulfate sodium (AOM-DSS) and dimethylhydrazine (DMH)—show that probiotic supplementation reduces tumor burden, strengthens tight junctions (TJ) through proteins like claudin-1 and zonula occludens-1, and restores the intestinal barrier that chronic inflammation erodes. Given that barrier breakdown and inflammation are early steps in colorectal carcinogenesis, this protective activity is particularly meaningful.

The review is careful to acknowledge the limitations of the current evidence base. Nearly all of the findings it compiles come from cell culture and animal studies; clinical trials in cancer patients remain sparse, and dosing, strain specificity, and safety profiles are far from standardized. Effects observed with one bacterial strain cannot be assumed for another, and the composition of an individual’s existing microbiome may dramatically alter any probiotic’s impact. The authors emphasize that the medical use of probiotics in oncology must rest on an extensive understanding of the molecular and cellular mechanisms underlying their anticancer activities—precisely the kind of mechanistic synthesis their review provides.

The concept of next-generation probiotics (NGPs) also features in the discussion, pointing toward engineered or precisely selected strains designed for specific therapeutic purposes rather than broad wellness claims. Combined with postbiotic formulations that eliminate the infection risk of live bacteria, the field is converging on a vision of microbe-based oncology that is targeted, mechanistically grounded, and compatible with existing treatments. If that vision matures, the humble bacteria in fermented foods may find themselves repurposed as precision allies in one of medicine’s hardest fights.